CompletedPhase 2NCT02864082
A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis
Studying Autosomal recessive congenital ichthyosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Patagonia Pharmaceuticals, LLC
- Principal Investigator
- Zachary Rome, BSSponsor GmbH
- Intervention
- PAT-001, 0.1%(drug)
- Enrollment
- 19 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2017 – 2018
Study locations (5)
- TCR Medical Corporation, San Diego, California, United States
- Yale Center for Clinical Investigation, New Haven, Connecticut, United States
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- Paddington Testing Co., Inc, Philadelphia, Pennsylvania, United States
- Texas Dermatology and Laser Specialists, San Antonio, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02864082 on ClinicalTrials.gov